

Randall J Brezski

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9109838/publications.pdf>

Version: 2024-02-01

31
papers

2,061
citations

331670

21
h-index

477307

29
g-index

32
all docs

32
docs citations

32
times ranked

3510
citing authors

#	ARTICLE	IF	CITATIONS
1	IgG Fc engineering to modulate antibody effector functions. <i>Protein and Cell</i> , 2018, 9, 63-73.	11.0	242
2	Effector-attenuating Substitutions That Maintain Antibody Stability and Reduce Toxicity in Mice. <i>Journal of Biological Chemistry</i> , 2017, 292, 3900-3908.	3.4	206
3	Tonic B cell antigen receptor signals supply an NF- κ B substrate for pro-survival BLyS signaling. <i>Nature Immunology</i> , 2008, 9, 1379-1387.	14.5	190
4	A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor-Resistant Lung Tumors. <i>Cancer Research</i> , 2016, 76, 3942-3953.	0.9	165
5	Trastuzumab Triggers Phagocytic Killing of High HER2 Cancer Cells In Vitro and In Vivo by Interaction with Fc γ 3 Receptors on Macrophages. <i>Journal of Immunology</i> , 2015, 194, 4379-4386.	0.8	150
6	Cleavage of IgGs by proteases associated with invasive diseases. <i>MAbs</i> , 2010, 2, 212-220.	5.2	130
7	An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations. <i>Methods</i> , 2014, 65, 114-126.	3.8	127
8	Proteolytic Cleavage and Loss of Function of Biologic Agents That Neutralize Tumor Necrosis Factor in the Mucosa of Patients With Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2015, 149, 1564-1574.e3.	1.3	105
9	Tumor-Associated Macrophages Promote Invasion while Retaining Fc-Dependent Anti-Tumor Function. <i>Journal of Immunology</i> , 2012, 189, 5457-5466.	0.8	97
10	Tumor-associated and microbial proteases compromise host IgG effector functions by a single cleavage proximal to the hinge. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 17864-17869.	7.1	83
11	Immunoglobulin isotype knowledge and application to Fc engineering. <i>Current Opinion in Immunology</i> , 2016, 40, 62-69.	5.5	61
12	Membrane Cholesterol Content Accounts for Developmental Differences in Surface B Cell Receptor Compartmentalization and Signaling. <i>Journal of Biological Chemistry</i> , 2005, 280, 25621-25628.	3.4	59
13	A single proteolytic cleavage within the lower hinge of trastuzumab reduces immune effector function and in vivo efficacy. <i>Breast Cancer Research</i> , 2012, 14, R116.	5.0	53
14	Avidity confers Fc γ 3R binding and immune effector function to aglycosylated immunoglobulin G1. <i>Journal of Molecular Recognition</i> , 2012, 25, 147-154.	2.1	48
15	Human Anti-IgG1 Hinge Autoantibodies Reconstitute the Effector Functions of Proteolytically Inactivated IgGs. <i>Journal of Immunology</i> , 2008, 181, 3183-3192.	0.8	40
16	B-Cell Receptor. <i>Advances in Experimental Medicine and Biology</i> , 2008, 640, 12-21.	1.6	38
17	The in vitro resistance of IgG2 to proteolytic attack concurs with a comparative paucity of autoantibodies against peptide analogs of the IgG2 hinge. <i>MAbs</i> , 2011, 3, 558-567.	5.2	34
18	Engineered Protease-resistant Antibodies with Selectable Cell-killing Functions. <i>Journal of Biological Chemistry</i> , 2013, 288, 30843-30854.	3.4	33

#	ARTICLE	IF	CITATIONS
19	An Fc engineering approach that modulates antibody-dependent cytokine release without altering cell-killing functions. <i>MAbs</i> , 2015, 7, 494-504.	5.2	32
20	B Cell Antigen Receptor-Induced Rac1 Activation and Rac1-Dependent Spreading Are Impaired in Transitional Immature B Cells Due to Levels of Membrane Cholesterol. <i>Journal of Immunology</i> , 2007, 179, 4464-4472.	0.8	25
21	A monoclonal antibody against hinge-cleaved IgG restores effector function to proteolytically-inactivated IgGs in vitro and in vivo. <i>MAbs</i> , 2014, 6, 1265-1273.	5.2	23
22	The Origins, Specificity, and Potential Biological Relevance of Human Anti-IgG Hinge Autoantibodies. <i>Scientific World Journal</i> , The, 2011, 11, 1153-1167.	2.1	20
23	Dysfunctional Antibodies in the Tumor Microenvironment Associate with Impaired Anticancer Immunity. <i>Clinical Cancer Research</i> , 2015, 21, 5380-5390.	7.0	19
24	A Novel Therapeutic Strategy to Rescue the Immune Effector Function of Proteolytically Inactivated Cancer Therapeutic Antibodies. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 681-691.	4.1	18
25	Structure and specificity of an antibody targeting a proteolytically cleaved IgG hinge. <i>Proteins: Structure, Function and Bioinformatics</i> , 2014, 82, 1656-1667.	2.6	15
26	Domain-Specific Antibodies Reveal Differences in the Membrane Topologies of Apolipoprotein L1 in Serum and Podocytes. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 2065-2082.	6.1	15
27	A peptide immunization approach to counteract a <i>Staphylococcus aureus</i> protease defense against host immunity. <i>Immunology Letters</i> , 2016, 172, 29-39.	2.5	10
28	Molecular characterization of human anti-hinge antibodies derived from single-cell cloning of normal human B cells. <i>Journal of Biological Chemistry</i> , 2018, 293, 906-919.	3.4	7
29	Application of Antibody Engineering in the Development of Next Generation Antibody-Based Therapeutics. , 2012, , 65-93.		2
30	BCR-linked Factors in Developmental Fate Decisions. , 2007, 596, 47-55.		1
31	Novel Generation of Antibody-Based Therapeutics. , 2015, , 125-146.		0